Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 6
Opinion
Video
Gene Therapy Data for BCG-Unresponsive NMIBC
Author(s):
Key Takeaways
- BCG-unresponsive NMIBC is defined by persistent or recurrent high-grade tumors or carcinoma in situ after adequate BCG therapy.
- This condition requires alternative therapeutic strategies or radical cystectomy due to the failure of BCG treatment.
Katie S. Murray, DO, discusses the promising clinical trial data showing that over 50% of patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) experience a complete response after 3 months of treatment, comparing these outcomes with her own clinical experience, and highlights the importance of long-term follow-up to assess the durability of response in patients receiving newer therapies.
- Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings?
- How do these clinical trial outcomes compare with what you see in your clinical practice when treating patients with newer therapies
- Discuss the importance of long-term follow-up for patients receiving these newer treatments.
a. What is your experience in terms of durability of response?
Related Videos
Related Content
